To the Editor: In Taiwan, the incidence of tuberculosis (TB) was 74.1/100,000 population in 2004 and 72.7/100,000 in 2005; the mortality rate was 4.2/100,000 in 2004 and 4.3/100,000 in 2005 (1) . Because of these high incidences and the increasing effects of multidrug-resistant TB (MDR TB), i.e., resistant to at least both isoniazid (INH) and rifampin (RIF), the laboratory-based Taiwan Surveillance of Drug Resistance in TB (TSDRTB) program was established in 2003 (2) . Surveillance demonstrated that combined drug resistance rates were 11.3% (2004) Extensively drug-resistant TB (XDR TB) was initially defi ned as an MDR isolate that was resistant to at least 3 of the 6 main classes of secondline drugs: aminoglycosides, polypeptides, fl uoroquinolones, thioamides, cycloserine, and para-aminosalicylic acid (4). In October 2006, the World Health Organization (WHO) redefi ned XDR TB as an isolate "resistant to at least INH and RIF (i.e., MDR TB) plus resistant to at least 1 of the fl uoroquinolones and 1 of the following 3 injectable drugs: capreomycin, kanamycin, and amikacin" (5) . Clearly, XDR TB is a global threat and the demands on XDR TB surveillance systems are urgent.
Because no guidelines for drug susceptibility testing of second-line drugs existed in Taiwan before 2007, clinical mycobacteriology laboratories performed drug susceptibility testing of second-line drugs using the agar proportion method by clinicians' request only. Critical concentrations of second-line drugs for drug susceptibility testing were 2 μg/mL for ofl oxacin, 6 μg/mL for kanamycin, 10 μg/mL for ethionamide, and 8 μg/ mL for para-aminosalicylate. With their broad spectrum antimicrobial activity, fl uoroquinolones are widely used for the treatment of bacterial respiratory infections in Taiwan. In addition, fl uoroquinolones are the preferred oral agents for treating drug-resistant TB that is known or presumed to be sensitive to this class of drugs, or when fi rst-line agents cannot be used because of intolerance (6) . In contrast to injectable agents that have a higher incidence of renal and hearing impairment after longterm use, fl uoroquinolones have high oral bioavailability, convenient dosing intervals, and a lower incidence of side effects (7). Therefore, despite TB treatment recommendations, some clinicians prescribe fl uoroquinolones instead of injectable agents. A previous study by Yu et al. (8) showed that fl uoroquinolone-resistant Mycobacterium tuberculosis isolates were rare among patients not previously exposed to fl uoroquinolones; however, the increased rate of resistance to fl uoroquinolones was observed among patients with MDR TB because of inadequate treatment regimens or poor compliance (8, 9) .
In this study, 215 MDR isolates were tested; among these, 42.8% (92/215) were fl uoroquinolone-resistant, a much higher percentage than the 10.2% (22/215) that fulfi lled the defi nition of XDR TB. Because the adequate use of fl uoroquinolones for TB per WHO and national guidelines (either for intolerance or drug resistance) is important, the use of fl uoroquinolones is strictly regulated by the National Health Insurance program. Since 2007, clinicians in Taiwan have been required to apply for these and second-line drugs through the Taiwan Centers for Disease Control (CDC) and to accept professional supervision in their administration. Furthermore, these drugs can only be given under the direct observed treatment program.
An outbreak in rural South Africa highlighted the risk of XDR TB for persons co-infected with HIV (10). The current Taiwan TB and HIV Register shows that <1% of TB patients are co-infected with HIV and documents no XDR TB patients who are co-infected with HIV. However, because persons co-infected with HIV and M. tuberculosis have the highest rates of progression to active disease, continued monitoring of co-infected patients is essential for control of TB.
The initial purpose of the TS-DRTB program was to survey drug resistance of fi rst-line anti-TB drugs in Taiwan. Therefore, our study data are limited; the rate of XDR TB among MDR TB may be an underestimate because we did not have adequate representative cases and methods. The present surveillance system does clearly show the emergence of XDR TB cases in Taiwan, which highlights the need to reinforce diagnosis and treatment strategies recommended by the National TB Control Program. In addition to the established TSDRTB program, Taiwan CDC started an enhanced population-based surveillance of MDR TB/XDR TB in 2007. 
